gabexate has been researched along with Experimental Hepatoma in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamauchi, Y | 1 |
| Kobayashi, M | 1 |
| Watanabe, A | 1 |
1 other study available for gabexate and Experimental Hepatoma
| Article | Year |
|---|---|
Anti-carcinogenic effects of a serine protease inhibitor (FOY-305) through the suppression of neutral serine protease activity during chemical hepatocarcinogenesis in rats.
Topics: Animals; Antineoplastic Agents; Carbon Tetrachloride; Endopeptidases; Esters; Gabexate; gamma-Glutam | 1987 |